Hidradenitis suppurativa (HS) Learning Zone
Transcript: Standard of care for HS
Dr Thrasyvoulos Tzellos
Interview recorded Sep 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
One important was the concept of moisture-associated skin damage. So an interesting concept in studies showing that changing the moisture environment in HS where we have skin to skin contact, and with the correct use of barrier creams or other topical solutions, and a nice follow up may be beneficial because it has been shown that moisture-associated skin can facilitate further inflammation. We saw some interesting data regarding the development of squamous cell carcinoma in chronic HS patients, especially in Hurley 3, in severe HS. And we saw an interesting systematic review of the whole literature identifying Hurley 3, so more severe disease, and longer duration of the disease and not correct treatment of the disease, but also perhaps the TNF use.
The anti-TNF use is important points for this development. And we have to keep in mind that if we see HS in a specific part that does not heal, always think of a possible biopsy to exclude malignant transformation. Furthermore, we saw some evidence regarding lutikizumab, an inhibitor that inhibits combined both in interleukin-1α into 1β, from the phase 3 programme. And what was important was that, in the phase 2 programme, these patients under lutikizumab were already patients that did not respond to standard care with adalimumab or another anti-TNF, so they were not responders. And still this group achieved a significant effect, both for a high score and IHS4 under lutikizumab treatment. So a promising agent as well. It is always exciting to hear regarding good healing. We saw some studies using PRP, for example, that could facilitate good healing. And of course, good healing is always an important factor after surgery. But also when we have primary hood, for example, in draining tunnels.
This content has been developed independently by Medthority who previously received educational funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.